From a $1.2M gene therapy to a $450K lymphoma med, these are the 10 priciest medications out there.
from FiercePharma
FiercePharma takes a look at the ten priciest medications, including a treatment for lipoprotein lipase deficiency (Glybera, $1.21 million per year), a treatment for urea cycle disorders (Ravicti, $793,632), a therapy used to treat Pompe disease (Lumizyme, $626,400), and more.
Disclaimer: The viewpoint expressed in this article is the opinion of the author and is not necessarily the viewpoint of the owners or employees at Healthcare Staffing Innovations, LLC.
The three plaintiffs are seeking damages from Mylan to represent a nationwide class of EpiPen purchasers.
from Reuters
The lawsuit was filed on Monday in Tacoma, Washington, federal court by three EpiPen purchasers. It claims Mylan engaged in a scheme with pharmacy benefit managers, or PBMs – companies that act as intermediaries between pharmacies, insurers and drug companies – to dominate the market and overcharge consumers. Although other lawsuits have been filed over EpiPen pricing, Monday’s is the first to focus on the role of PBMs and to bring claims under the Racketeer Influenced and Corrupt Organizations Act, a federal law historically used against organized crime.
Disclaimer: The viewpoint expressed in this article is the opinion of the author and is not necessarily the viewpoint of the owners or employees at Healthcare Staffing Innovations, LLC.
A new study found that Big Pharma makes more from high U.S. drug prices than it spends on research around the world.
from FiercePharma
Sure to add fuel to the fiery U.S. drug pricing debate, new work from several health policy experts showed that pharma makes more from platinum pricing in the U.S. than it spends on research around the world.
Disclaimer: The viewpoint expressed in this article is the opinion of the author and is not necessarily the viewpoint of the owners or employees at Healthcare Staffing Innovations, LLC.
